HopeStage
Back to all studies
CompletedNCT01427608

Medication Combinations to Sustain Improvement in Psychotic Depression

About this titleRead the official source — NCT01427608
Medication studyAges 18–85United States + Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 85 years.

Listed locations
Worcester and 3 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2011
Recruitment status
Completed
Enrollment listed in the registry
269
Sponsor
Weill Medical College of Cornell University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States, Canada
Age range
From 18 Years to 85 Years
Official registry ID
NCT01427608
Official title
Show the full official title

Sustaining Remission of Psychotic Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Worcester, United States · White Plains, United States · Pittsburgh, United States

1 more locations
  • Toronto, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Weill Medical College of Cornell University, a university.

Did this study involve medication?

Yes. The study involved medication, including Sertraline + Olanzapine and Sertraline + Placebo.

Who was this study for?

Listed age limits: 18 years to 85 years.

Want to explore more studies?

Explore studies